COEP
Coeptis Therapeutics, Inc.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
2.87
P/S
30.14
EV/EBITDA
-3.02
DCF Value
$3.16
FCF Yield
-20.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
-207.8%
Operating Margin
-956.9%
Net Margin
-611.1%
ROE
-78.8%
ROA
-42.0%
ROIC
-55.7%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $862.0K | $-5.2M | $-0.29 |
| FY 2025 | $1.4M | $-11.9M | $-2.81 |
| Q3 2025 | $237.4K | $-159.4K | $-0.58 |
| Q2 2025 | $200.7K | $-3.5M | $-0.95 |
Trading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
-0.43
Coeptis Therapeutics, Inc., a biopharmaceutical company, develops and commercializes generic and branded pharmaceutical products and cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a Vy-Gen drug product for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; and CD38-Diagnostic, an in vitro screening tool to provide the ability to pre-determine which cancer patients are most likely to benefit from targeted anti-CD38 monoclonal antibodies therapies. The company has collaboration with Statera BioPharma to develop and commercialize STAT-201 for Crohn's disease; and Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. Coeptis Therapeutics, Inc. was founded in 2017 and is headquartered in Wexford, Pennsylvania.